企業プロフィール · Healthcare

Pfizer Inc

PFE · 米国株
取引所
米国株
国 / 地域
USA
上場日
1942年6月22日
従業員数
75,000
公式サイト
www.pfizer.com
現在値
$25.21
リアルタイム · 2026年6月18日
ベイリー成長スコア
40/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 $25.21 リアルタイム · 妥当な本源的価値レンジ内

総合バリュエーションレンジ · 保守的 $16–$19 / 妥当 $24–$28 / 楽観的 $32–$36。$25.21 時点で 妥当な本源的価値レンジ内。

レポート公開時 $25.85(2026年5月25日)

この銘柄のレポートはお使いの言語でまだありません。

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

時価総額$1477.3億
売上高(TTM)$633.15億
EBITDA$254.6億
純利益率11.83%
ROE8.31%
PER (TTM)19.79
予想PER8.79
PEG3.77
EPS$1.31
配当利回り6.61%
52週レンジ$21.97 – $28.28
アナリスト目標株価$29.19
アナリスト評価3.6 / 5

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。